Operating loss: KRW 2.17bn (vs loss of KRW 1.84bn); Net loss: KRW 2.26bn (vs loss of KRW 2.03bn) → wider losses
Cancellation of 1,577,565 treasury shares (Feb 24, 2026) and additional 722,224 shares (Apr 10, 2026) → enhanced shareholder return
Capital surplus includes KRW 1.0bn from treasury share disposal; other equity components reflect treasury shares at -KRW 3.0bn (vs -KRW 12.4bn at year-end)
Cash and cash equivalents: KRW 25.1bn (down from KRW 27.7bn); borrowings: KRW 4.8bn (up from KRW 3.0bn) → slight deterioration in liquidity
FVTPL financial assets: KRW 13.5bn (vs KRW 16.1bn), valuation loss of KRW 0.79bn
Trade receivables: KRW 3.3bn (vs KRW 0.9bn), allowance for doubtful accounts ratio 37.2%
Equity method investments: loss of KRW 19mn, carrying value KRW 5.4bn
4 lawsuits pending: 2 as defendant (KRW 3.2bn), 2 as plaintiff (KRW 5.3bn) → contingent liabilities
Debt ratio: 9.71% (vs 6.37%), still low
R&D expenses: KRW 1.24bn (65.7% of sales), continued pipeline development at R&BD center
DR (diagnostics) segment: KRW 1.74bn (92.5% of sales); New drug segment: KRW 0.14bn (7.5%) → dominant diagnostics
Subsidiary iNtODEWORLD liquidated in Q1 2026; no consolidated financial statements prepared